[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stem-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stem-cell":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,75,115,135,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100358467","phase-2-autologous-volar-fibroblast-injection-into-the-stump-site-of-amputees-100358467",false,"NCT03947450","Autologous Volar Fibroblast Injection Into the Stump Site of Amputees","Inclusion Criteria:\n\nPatients interested in study participation must meet all of the following inclusion criteria:\n\n* May be male or female\n* Must be between 18 years and 65 years of age\n* Must have a below the knee amputation.\n* Must be using a prosthetic for the vicinity of 3 months or have had osteo-integration of a prosthetic in place for 1 month.\n* In the opinion of the investigator, must be medically able to undergo the administration of study material determined by laboratory tests obtained within 7 days before baseline for which the investigator identified no clinically significant abnormality.\n* Be able to comprehend the informed consent document and provide consent for participation\n* Females of childbearing potential must:\n\n  * have a negative pregnancy test at screening\n  * agree to not become pregnant or breastfeed for the period of the study through 1 month after completion of the study\n  * be willing to use a reliable form of contraception during the study\n* Be willing and able to comply with the scheduled visits, biopsy\u002Finjection procedures, wound care instructions treatment plan, and other study procedures for the duration of the study.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be ineligible for study participation:\n\n* A skin erosion deeper than the skin dermis.\n* Having received any investigational drug within 30 days prior to study entry\n* An allergy history to any study materials including local anesthetic, dimethyl sulfoxide, human albumin, or bovine constituents, hetastarch, or EMLA (lidocaine 2.5% and prilocaine 2.5%).\n* Pregnant, lactating, or trying to become pregnant\n* A history of keloid formation\n* Having a significant medical history that the investigator feels is not safe for study participation (for example, some forms of autoimmune conditions, metastatic cancer, infectious diseases such as HIV, HTLV I\u002FII, Hepatitis B, Hepatitis C). Biopsies taken from individuals with infections that are not allowed to enter the cell therapy core will make it such that these individuals cannot participate.\n* Specifically we will exclude those with autoimmune diseases affecting the skin such as lupus.\n* Presence of necrotic ischemic tissue on any stump ulcers, and\u002For capillary refill on stump skin of greater than 3 seconds\n* Active infection of the residual limb.\n* Active smoker during the study\n* We will also exclude those who are on chronic immunosuppressive therapies such as oral steroids, but also those on chronic topical steroids in the area of investigation.\n* Recent amputee who has not yet been approved to use a prosthetic.\n* Use of a prosthetic for less than 3 months.\n* Amputees with neuromas of the terminal limb within the last 3 months.\n* Known bleeding disorder.\n* For those receiving Bellafill\u002Fcollagen skin test: history of serious allergy, such as anaphylaxis.\n* For whole stump injections: Have a history of congenital or idiopathic methemoglobinemia, glucose-6-phosphate deficiencies, or use of medications associated with drug-induced methemoglobinemia. (specifically: Sulfonamides, Acetaminophen, Acetanilid, Aniline dyes, Benzocaine, Chloroquine, Dapsone, Naphthalene, Nitrates and Nitrites, Nitrofurantoin, Nitroglycerin, Nitroprusside, Pamaquine, Para-aminosalicylic acid, Phenacetin, Phenobarbital, Phenytoin, Primaquine, or Quinine.)",true,"ALL","18 Years","65 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a clinical trial testing the safety and efficacy of volar fibroblast (skin cells from the palm or sole) injections for thickening the epidermal (skin) layer at the stump site in people with below the knee amputations. The study will enroll adults seen at Johns Hopkins.",[27,28,29],"Amputation","Skin Wound","Stem Cell",[31,32,33,34,35],"amputation","stem cells","autologous fibroblast","skin wound","skin breakdown","RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-09","ACTUAL",{"date":42,"type":40},"2019-09-05",{"date":44,"type":21},"2028-04-01",{"name":46,"class":47},"Johns Hopkins University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100640127","augmentation-of-arthroscopic-rotator-cuff-repair-with-reimplantation-of-subacromial-bursa-tissue-and-platelet-rich-plasma-100640127","NCT07589478","Augmentation of Arthroscopic Rotator Cuff Repair With Reimplantation of Subacromial Bursa Tissue and Platelet-Rich Plasma","ΕΝΙΣΧΥΣΗ ΑΡΘΡΟΣΚΟΠΙΚΗΣ ΣΥΡΡΑΦΗΣ ΣΤΡΟΦΙΚΟΥ ΠΕΤΑΛΟΥ ΜΕ ΕΠΑΝΕΜΦΥΤΕΥΣΗ ΙΣΤΟΥ ΤΟΥ ΥΠΑΚΡΩΜΙΑΚΟΥ ΘΥΛΑΚΟΥ ΚΑΙ ΠΛΑΣΜΑΤΟΣ ΠΛΟΥΣΙΟΥ ΣΕ ΑΙΜΟΠΕΤΑΛΙΑ","Inclusion Criteria Adult patients aged ≥18 years. Patients undergoing arthroscopic rotator cuff repair. Patients with a full-thickness, isolated, primary tear of the supraspinatus tendon.\n\nPatients considered eligible for arthroscopic rotator cuff repair using suture anchors.\n\nAbility and willingness to provide written informed consent. Willingness and ability to comply with the study protocol and scheduled follow-up visits.\n\nExclusion Criteria Partial-thickness rotator cuff tears. Massive or irreparable rotator cuff tears. Revision rotator cuff repair. Concomitant tears of the subscapularis tendon, infraspinatus tendon, long head of the biceps tendon requiring surgical treatment, or glenoid labrum.\n\nPrevious surgery on the affected shoulder. Glenohumeral osteoarthritis or advanced cuff tear arthropathy. Active infection or systemic inflammatory disease affecting the shoulder. Use of other biological augmentation techniques during surgery, such as collagen patch, stem cells, bone marrow aspirate concentrate, or other scaffold-based augmentation.\n\nInability to provide informed consent. Inability or unwillingness to comply with the postoperative rehabilitation protocol or follow-up schedule.",{"count":57,"type":21},200,[59],"NA","The goal of this observational study is to evaluate the clinical and radiographic outcomes of the biological enhancement of the arthroscopic rotator cuff repair with stem cells from the acromial bursa and PRP in individuals who undergo arthroscopic cuff repair The main question it aims to answer is:\n\nDo the stems cells from the acromial bursa and PRP promote healing and produce better results in arthroscopic cuff repair? Researchers will compare this population to three others the first do bnot receive any biological enchancement, the second receive only stem cells and the third receive only PRP to see if there are any differences.",[62,63,29,64],"Cuff Injury, Rotator","Arthroscopic Surgical Procedures","PRP","NOT_YET_RECRUITING","2026-05-17",{"date":68,"type":40},"2026-05-19",{"date":70,"type":21},"2026-05",{"date":72,"type":21},"2028-02",{"name":74,"class":47},"National and Kapodistrian University of Athens",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":15,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":48},"100610461","early-phase-1-secretome-treatment-for-facial-rejuvenation-100610461","NCT07227883","Secretome Treatment for Facial Rejuvenation","Blinded, Randomized, Controlled, Trial to Evaluate the Efficacy and Safety of Autologous Hair Follicle Secretome for Facial Rejuvenation","Inclusion Criteria\n\n* Male or Female\n* Age: ≥30 and ≤ 75 at the time of consent.\n* Fitzpatrick skin types I-V\n* Moderate to very severe facial aging according to the SASSQ for the categories of elasticity, wrinkles, and skin roughness.\n* Willing to refrain from cosmetic procedures throughout the study period (i.e. laser treatments, chemical peels, microneedling, dermal filler injections, neuromodulator injections, etc.)\n* Willing to use study support products as directed and will not introduce any new skin care or makeup products throughout the study period. Subjects will be provided with a Skincare Kit: Cetaphil Gentle Skin Cleanser 20 oz, Cetaphil Daily Hydrating Lotion 3 oz, Cetaphil Sheer Mineral Liquid Face Sunscreen SPF 50 . Two of each will be provided with application instructions.\n* Male subjects with facial hair must be willing to shave the morning of their treatments\u002Ffollow-up visits.\n* Willing to minimize sun\u002Fultraviolet light exposure for the duration of the study, including all of the following: applying sunscreen daily, at least 15 minutes before going outside; wearing sun-protective clothing (e.g., a hat, sunglasses) when outdoors; reapplying sunscreen every 2 hours during outdoor activities; avoiding tanning bed\u002Ftanning product use.\n* Competent and willing to provide written, informed consent to participate in all study activities\n* Willing and able to tolerate multiple injections and attend all study visits\n* Negative urine pregnancy test result at the time of screening (if applicable)\n* For female subjects of childbearing potential, must be willing to use an acceptable form of birth control (oral contraceptives, hormonal implants, intrauterine device \\[IUD\\], hormonal injectables specifically for birth control, contraceptive patch or ring, tubal ligation \\[tubes tied\\], or total sexual abstinence) during the entire course of the study. All systemic birth control measures (oral, hormonal implants, injectables) must be in consistent use for at least 30 days prior to study enrollment. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and\u002For both ovaries, or has had a bilateral tubal ligation.\n\nExclusion Criteria\n\n* Use of topical tretinoin, adapalene, tazarotene, hydroquinone, imiquimod, 5-fluorouracil, ingenol mebutate, concentrated hydrogen peroxide, diclofenac, vitamin C, alpha hydroxy acids, or photodynamic therapy (PDT) to the face within 4 weeks prior to baseline photography and throughout the study period\n* Dermatologic diseases or conditions (e.g. atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, wounds, infections, irritation, sunburn, windburn, etc.) in the treatment area that could interfere with the study, in the opinion of the Investigator\n* Starting use or stopping use of GLP-1 agonists, or planned weight loss or gain during the study period. Subjects using GLP-1 agonists must be taking the drug for maintenance AND body weight must have been stable for at least 3 months prior to initial study treatment.\n* History of keloid formation, hypertrophic scarring, or abnormal\u002Fdelayed wound healing\n* Previous medical aesthetic rejuvenation treatments on the face, such as chemical peel, dermabrasion, non-ablative or ablative resurfacing procedure, or face-lift with laser or other devices, up to 3 months prior to baseline photography\n* Treatment with neuromodulators in crow's feet, glabellar region, or frontalis muscles within 4 months prior to baseline photography\n* Treatment with dermal fillers, collagen stimulators, fat injections or permanent fillers within the past 6 months prior to baseline photography.\n* Patients using other anti-aging treatments\u002Fprocedures\u002Fsystemic medications or injections administered\u002Fprescribed by a medical professional before starting the study, if the investigator believes they will confound the results. Consulting with Sponsor is encouraged.\n* Heavy smoker (\\>1 pack of cigarettes a day)\n* Energy-based device (i.e., radiofrequency device treatments, microfocused ultrasound device or other ultrasound-based device treatments, laser and light-based device treatments, microneedling) treatment in the treatment area within 6 months prior to baseline photography\n* Currently be taking isotretinoin (Accutane).\n* Subjects on an immunosuppressant or have an autoimmune condition (except stable, controlled Hashimoto's thyroiditis)\n* Surgery (i.e., face lift, eyebrow lift, neck lift or lower rhytidectomy, liposuction, etc.) during the 12-month period prior to baseline photography\n* Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study\n* Severe active infection (e.g. HIV, HepB or C, UTI, etc.)\n* Current or recent (within last 5 years) malignancy (except basal cell and squamous cell skin cancers as long as basal cell was not on the face)\n* History of systemic chemotherapy or radiation within the last 5 years\n* Continuous\u002Fdaily use of nonsteroidal anti-inflammatory or Vitamin E, unless discontinued within 7 days before 1st treatment and only used as needed through the trial period.\n* Anticipated pregnancy or trying to become pregnant in the next year\n* Current anticoagulant therapy (heparins; factor Xa inhibitors; direct agents such dabigatran, rivaroxaban, apixaban, endoxaban and betrixaban; warfarin\u002Fcoumarins). Low dose aspirin and omega-3 supplements allowed.\n* Any other criterion that is based on the clinical judgment of the investigator may place the subject at risk or confound study results","30 Years","70 Years",{"count":85,"type":21},24,[87],"EARLY_PHASE1","Secretome treatment for facial rejuvenation",[90,91,29,92],"Facial Aging","Rejuvenation","Stem Cell Banking",[32,94,95,96,97,98,99,100,101,102,103,104],"secretome","autologous","hair follicle","aging","facial","face","under eyes","wrinkles","anti-aging","rejuvenation","regeneration","2026-04-30",{"date":107,"type":40},"2026-05-04",{"date":109,"type":40},"2025-12-15",{"date":111,"type":21},"2026-12-20",{"name":113,"class":114},"Acorn Biolabs Inc.","INDUSTRY",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":48},"100516403","safety-tolerability-and-efficacy-of-enteral-nutrition-versus-standard-of-care-nutrition-in-hematopoietic-stem-cell-transplant-patients-a-pilot-study-100516403","NCT06004063","Safety, Tolerability, and Efficacy of Enteral Nutrition Versus Standard of Care Nutrition in Hematopoietic Stem Cell Transplant Patients: A Pilot Study","Inclusion Criteria:\n\n1. Have plans to be admitted or be admitted to an inpatient pediatric or adult ward for the purpose of HSCT.\n2. Be greater than 2 years of age and less than 25 years of age at time of study enrollment.\n3. Participants \\> 18 or guardians for participants \\\u003C 18 are willing and able to give written informed consent and to comply with all of the study activities. Assent is required for children \\> 7 years old.\n\n   a) Participants must be English, Italian, Chinese\u002FMandarin, or Spanish speaking\n4. Participants will be encouraged to co-enroll on two additional related energy -balance protocols (highly encouraged but not required)\n\n   1. MDACC protocol PA18-0130. This protocol will enable us to track physical activity through their receipt of a Fitbit (Pediatric Energy Balance Data Repository Protocol.) , and\n   2. MDACC protocol LAB99-062 \"A Study to Collect Peripheral Blood, Tissue, and Bone Marrow samples from Donors and Recipients of blood and marrow transplants for Laboratory Research\" which will allow collection of stool for exploration of the effects of feeding on microbiome data specifically.\n5. Participants will be asked to consider co-enrollment on Stem Cell Registry study (not required):\n\n   1. PA19-0756: This is a prospective multi-center study to understand the contribution of vascular endothelial dysfunction towards morbidity and mortality among children and adolescents\u002Fyoung adults (AYA) undergoing HCT\u002FCT.\n\nExclusion Criteria:\n\n1. Patients in whom EN is contraindicated (e.g intestinal ischemia, complete bowel obstruction, or other anatomical obstructive process), or all available routes of EN are contraindicated. Surgical GT placements for the sole purpose of study participation will not be entertained. See Table 1\n2. Females who are pregnant. We follow FACT guidelines. Per Foundation for the Accreditation of Cellular Therapy (FACT), female patients must have a negative pregnancy test 7 days prior to bone marrow transplant.",{"count":122,"type":21},40,[59],"The goal of this research study is to learn if feeding someone after a stem cell transplant is safe and practical.",[29],"2026-03-31",{"date":128,"type":40},"2026-04-02",{"date":130,"type":40},"2023-08-04",{"date":132,"type":21},"2029-12-31",{"name":134,"class":47},"M.D. Anderson Cancer Center",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":17,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":48},"100559485","stem-cell-applications-in-biliary-atresia-patients-100559485","NCT06564740","Stem Cell Applications in Biliary Atresia Patients","Umbilical Cord Derived Mesenchymal Stem Cell (UC-MSC) Transplantation in Infants with Biliary Atresia: a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Infants were diagnosed with liver cirrhosis due to biliary atresia following Kasai's operation.\n* The patients two months old or older and exhibited signs of cirrhosis after the procedure, including hepatomegaly, congestive splenomegaly, elevated liver enzymes, esophageal varices (confirmed by endoscopy), and cirrhosis (confirmed by liver biopsy).\n\nExclusion Criteria:\n\n* Epilepsy\n* Neurological disorders\n* Coagulation disorders\n* Diabetes\n* Syndromic type biliary atresia\n* Allergies to anesthetic agents\n* Severe health conditions such as cancer or failure of the heart, lungs, liver, or kidneys, active infections, and severe psychiatric disorders.","2 Months",{"count":144,"type":21},64,[59],"Recently, mesenchymal stem cell (MSC) transplantation has emerged as a promising treatment for liver cirrhosis in adults. Additionally, bone marrow-derived stem cell transplantation has shown success in treating children with biliary atresia (BA). This study aims to evaluate the efficacy of Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSC) therapy in BA through a multicentric randomized controlled trial.",[148,149,29],"Biliary Atresia","Fibrosis, Liver",[151,152,153],"biliary atresia","liver fibrosis","stem cell","2024-09-03",{"date":156,"type":40},"2024-09-19",{"date":158,"type":40},"2024-06-01",{"date":160,"type":21},"2026-06-01",{"name":162,"class":47},"Necmi Kadıoğlu Hospital",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":48},"100552979","phase-1-stem-cell-derived-exome-for-treatment-of-diabetic-foot-100552979","NCT06480123","Stem Cell Derived Exome for Treatment of Diabetic Foot","Skin Drug Prepared From Stem Cell Derived Exome for Treatment of Diabetic Foot: a Phase II Clinical Trial","Inclusion Criteria:\n\n1. Clinical diagnosis of diabetic foot.\n2. Signed informed consent before recruiting.\n3. Age above 18 years or less than 90 years.\n4. ECOG score \\\u003C 4\n5. Tolerable coagulation function or reversible coagulation disorders\n6. Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9\u002FL; Hb≥90g\u002FL； PLT ≥50×10E9\u002FL；INR \\\u003C 2.3 or PT \\\u003C 6 seconds above control；Cr ≤ 145.5 umul\u002FL；Albumin \\> 28 g\u002FL；Total bilirubin \\\u003C 51 μmol\u002FL\n7. Willing and able to comply with scheduled visits, treatment plan and laboratory tests.\n\nExclusion Criteria:\n\n1. Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks;\n2. Patients accompany by ascites, hepatic encephalopathy and esophageal and gastric varices bleeding;\n3. Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders;\n4. Patients have poor compliance.\n5. Allergic to the skin drug;\n6. Any agents which could affect the absorption or pharmacokinetics of the study drugs\n7. Other conditions that investigator decides not suitable for the trial.","90 Years",{"count":20,"type":21},[173,24],"PHASE1","This trial is designed to investigate the safety and efficacy of patients with diabetic foot by using stem cell derived exome.",[176,29],"Diabetic Foot",[178,179,180,181],"Diabetic foot","Stem cell","Exome","Skin drug","2024-06-26",{"date":184,"type":40},"2024-06-28",{"date":186,"type":21},"2024-08-01",{"date":188,"type":21},"2033-12-30",{"name":190,"class":47},"Second Affiliated Hospital of Guangzhou Medical University"]